Best peptides for fat loss in the UK

The fat-loss peptide landscape changed completely between 2017 and 2024. The arrival of GLP-1 receptor agonists — first liraglutide, then semaglutide, then tirzepatide — produced effect sizes that no prior pharmacological category had approached. UK readers now have several genuinely effective options, alongside a busy grey market of unlicensed compounds with thinner evidence.

This guide ranks the compounds by published clinical evidence — not by marketing volume — and is written for UK readers, with prescribing routes and legal status reflecting the May 2026 environment.

How we rank

Each compound is assessed on four criteria: phase-3 trial evidence (mean effect size, sample size, replication); UK regulatory status and accessibility; safety profile and tolerability; and durability of effect after discontinuation. We weight phase-3 RCT data heavily — phase-2 effect sizes systematically over-state what phase-3 confirms.

Peptides marketed for fat loss but lacking completed phase-3 evidence (or any human RCT data) are listed but with explicit confidence flags. Marketing claims for these compounds frequently extend beyond what the published evidence supports.

1. Tirzepatide (Mounjaro / Zepbound)

Currently the strongest-evidenced compound in any pharmacologic weight-management category. Mean weight reduction of −20.9% over 72 weeks at the 15mg dose in the SURMOUNT-1 phase-3 trial. Approved in the UK as both Mounjaro (type-2 diabetes) and for chronic weight management.

Available via NHS pathways for eligible patients (NICE TA1026) and through regulated private clinics. Counterfeit injector pens are a documented and ongoing safety problem — the MHRA has issued multiple alerts; supply via unregulated channels carries real risk.

2. Semaglutide (Wegovy / Ozempic)

The most-studied modern obesity drug. Mean weight reduction of −14.9% over 68 weeks at the 2.4mg dose (STEP-1). Smaller effect than tirzepatide, but with a larger long-term dataset and unique cardiovascular outcome evidence (SELECT trial: 20% MACE reduction in patients with established CVD and overweight/obesity).

Wegovy is licensed for chronic weight management; Ozempic for type-2 diabetes. Available on the NHS for narrow eligibility (NICE TA875) and through regulated private clinics. Counterfeit pens documented in 2024–2025.

3. Liraglutide (Saxenda)

A first-generation, daily-injection GLP-1 with mean weight reduction of approximately −8.0% over 56 weeks at the 3.0mg dose. Effective but largely superseded on both efficacy and convenience by the weekly options.

Worth knowing about for two reasons: it has the longest post-marketing safety dataset of any GLP-1, and the LEADER trial provided the original cardiovascular benefit signal in the GLP-1 class. UK NHS access via NICE TA664; widely available privately.

4. Retatrutide (investigational)

A triple GIP / GLP-1 / glucagon agonist in late-stage development. Phase-2 data show the largest weight reductions ever seen for a pharmacologic agent (−24.2% on 12mg over 48 weeks). Phase-3 program (TRIUMPH) is ongoing; primary readouts expected 2026–2027.

Not legally available outside clinical trials. Material sold under the name "retatrutide" through grey-market channels has no verified identity and should be assumed unsafe.

Compounds we don't recommend (and why)

AOD-9604: Marketed extensively as a "fat-loss peptide". Multiple phase-2 trials in the 2000s failed to demonstrate clinically meaningful weight reduction; the development programme was discontinued. Despite this, AOD-9604 remains widely sold via research-chemical channels — a clear case of marketing volume diverging from evidence base.

HGH fragment 176-191: A smaller AOD-9604-related fragment with even less human evidence. The lipolysis claims rely almost entirely on in-vitro and rodent data.

Tesamorelin: An exception to the "we don't recommend" framing — it has FDA approval for HIV-associated lipodystrophy and is genuinely effective in that specific context. But it is not approved for general weight management and the cost/access picture in the UK doesn't support general use.

A note on supply quality

The dominant practical risk in this category is not the compound itself but the supply chain. For licensed POMs (tirzepatide, semaglutide, liraglutide), supply via your GP, private prescriber, or registered pharmacy is the only fully assured route. Counterfeit injector pens have been found to contain insulin, saline, or different active ingredients entirely.

For unlicensed compounds, independent third-party testing has consistently documented identity failures and contamination. There is no regulatory body in the UK that vouches for "research chemical" peptide quality — and the absence of such oversight is the central reason most of those compounds rank poorly here on the practical-recommendation axis even where the underlying mechanism may be promising.